Diagnosis and Management of ANCA-Associated Vasculitis
Lancet 403:683-698, Kronbichler, A., et al, 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Clinical Presentation, Management, and Outcome in Neurolymphomatosis, A Systematic Review
Neurol 103:e209698, Kaulen.L.D.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Polymyalgia Rheumatica
Lancet 402:1459-1472, Espigol-Frigole,G.,et al, 2023
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
Second Drug Okayed for Rare Central Nervous System Disease
JAMA 324:224, Jaklevic, M.C., 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis
JAMA Neurol 74:60-66, Robeson, K.R.,et al, 2017
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017
Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort
Neurol 86:1683-1691,1655, Lee, W.J.,et al, 2016
Tocilizumab for Induction and Maintenance of Remission in Giant Cell Arteritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 387:1921-1927,1882, Villiger, P.M.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibodies - A Review
Ann Clin Trans Neurol 3:655-663, Venkatraman,A. & Opal,P., 2016
Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Bevacizumab in Glioblastoma - Still Much to Learn
NEJM 370:764-765, Fine, H.A., 2014
Safety and Efficacy of Ofatumumab in Relapsing-Remitting Multiple Sclerosis
Neurol 82:573-581, Sorensen, P.S.,et al, 2014